[go: up one dir, main page]

UY31061A1 - Tratamiento de la degeneracion macular relacionada con la edad mediante el uso de inhibidores del factor d del complemento - Google Patents

Tratamiento de la degeneracion macular relacionada con la edad mediante el uso de inhibidores del factor d del complemento

Info

Publication number
UY31061A1
UY31061A1 UY31061A UY31061A UY31061A1 UY 31061 A1 UY31061 A1 UY 31061A1 UY 31061 A UY31061 A UY 31061A UY 31061 A UY31061 A UY 31061A UY 31061 A1 UY31061 A1 UY 31061A1
Authority
UY
Uruguay
Prior art keywords
age
treatment
complement
factor
inhibitors
Prior art date
Application number
UY31061A
Other languages
English (en)
Inventor
Carmelo Romano
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of UY31061A1 publication Critical patent/UY31061A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

El presente invento provee métodos para identificar a los pacientes en riesgo de contraer una degeneracion muscular relacionada con la edad mediante la identificacion de la presencia del polimorfismo Y402H u otra variante de riesgo en el gen factor H del complemento.Asimismo, el presente invento provee métodos para el tratamiento de personas con degeneracion muscular relacionada con la edad o en riesgo de desarrollar dicha enfermedad por la presencia del polimorfismo Y402H u otra variante de riesgo en el gen factor H del complemento.
UY31061A 2007-04-30 2008-04-29 Tratamiento de la degeneracion macular relacionada con la edad mediante el uso de inhibidores del factor d del complemento UY31061A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91487707P 2007-04-30 2007-04-30

Publications (1)

Publication Number Publication Date
UY31061A1 true UY31061A1 (es) 2008-10-31

Family

ID=39586997

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31061A UY31061A1 (es) 2007-04-30 2008-04-29 Tratamiento de la degeneracion macular relacionada con la edad mediante el uso de inhibidores del factor d del complemento

Country Status (15)

Country Link
US (1) US20080269318A1 (es)
EP (1) EP2139471A2 (es)
JP (1) JP2010526074A (es)
KR (1) KR20100014486A (es)
CN (1) CN101674824A (es)
AR (1) AR066292A1 (es)
AU (1) AU2008248043A1 (es)
BR (1) BRPI0811007A2 (es)
CA (1) CA2680833A1 (es)
CL (1) CL2008001259A1 (es)
MX (1) MX2009009738A (es)
RU (1) RU2009144142A (es)
TW (1) TW200900056A (es)
UY (1) UY31061A1 (es)
WO (1) WO2008137236A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316394B1 (en) 2001-06-12 2016-11-23 The Johns Hopkins University Reservoir device for intraocular drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4 Inc Posterior segment drug delivery
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
HUE057267T2 (hu) * 2010-08-05 2022-05-28 Forsight Vision4 Inc Berendezés szem kezelésére
HUE054113T2 (hu) 2010-08-05 2021-08-30 Forsight Vision4 Inc Injekciós készülék gyógyszerbejuttatáshoz
EP2640360A2 (en) 2010-11-19 2013-09-25 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
RU2495650C1 (ru) * 2012-02-29 2013-10-20 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Трехкомпонентный комплекс для клеточной терапии в офтальмологии
RU2485922C1 (ru) * 2012-03-28 2013-06-27 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ лечения "сухой" формы возрастной макулярной дегенерации
RU2494711C1 (ru) * 2012-05-18 2013-10-10 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ хирургического лечения прогрессирующей и осложненной миопии
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
ES2972168T3 (es) 2013-03-28 2024-06-11 Forsight Vision4 Inc Implante oftálmico para administración de sustancias terapéuticas
CR20160132A (es) * 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
US11219552B2 (en) 2013-09-06 2022-01-11 The Regents Of The University Of Colorado, A Body Corporate Intraocular filter device and methods of using same
EP3041524A4 (en) * 2013-09-06 2017-06-14 The Regents of the University of Colorado, a body corporate Intraocular drug delivery and filter device and methods of using same
EP3054965B1 (en) * 2013-10-07 2021-04-14 Massachusetts Eye & Ear Infirmary Anti-factor d antibody for use in preventing or reducing retinal detachment
DE102014107380A1 (de) 2014-05-26 2015-11-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Verfahren zur Diagnose einer durch den alternativen Weg des Komplementsystems vermittelten Krankheit oder eines Risikos hierfür
KR101981532B1 (ko) 2014-06-12 2019-09-02 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
CA2957548A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
PL3250230T3 (pl) 2015-01-28 2022-02-14 Ra Pharmaceuticals, Inc. Modulatory aktywności dopełniacza
JP6912475B2 (ja) 2015-11-20 2021-08-04 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 持続放出性薬物送達機器用の多孔質構造体
RU2733720C2 (ru) 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
CN108934169A (zh) * 2016-01-20 2018-12-04 维特里萨医疗公司 用于抑制因子d的组合物和方法
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
AU2018250695A1 (en) * 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
TW201938184A (zh) 2017-12-04 2019-10-01 美商Ｒａ製藥公司 補體活性之調節劑
CN113543796A (zh) 2019-03-08 2021-10-22 Ra制药公司 齐鲁考普作为深层组织穿透性c5抑制剂
US20230115176A1 (en) 2019-03-29 2023-04-13 Ra Pharmaceuticals, Inc. Complement Modulators and Related Methods
US20220211799A1 (en) 2019-04-24 2022-07-07 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112022022980A2 (pt) 2020-05-12 2022-12-20 Alexion Pharma Inc Uso de inibidores de fator d de complemento sozinhos ou em combinação com anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna
CN114686481B (zh) * 2020-12-31 2023-08-15 北京键凯科技股份有限公司 一种抑制cfd表达的干扰rna及其制备方法和应用
WO2025199107A1 (en) 2024-03-19 2025-09-25 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653340B1 (en) * 1997-06-03 2003-11-25 Biocryst Pharmaceuticals, Inc. Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
US6413245B1 (en) * 1999-10-21 2002-07-02 Alcon Universal Ltd. Sub-tenon drug delivery
EP2026073B1 (en) * 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
EP2357257B1 (en) * 2005-02-14 2019-07-31 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
EP2148691B1 (en) * 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system

Also Published As

Publication number Publication date
CN101674824A (zh) 2010-03-17
JP2010526074A (ja) 2010-07-29
WO2008137236A2 (en) 2008-11-13
TW200900056A (en) 2009-01-01
US20080269318A1 (en) 2008-10-30
AU2008248043A1 (en) 2008-11-13
MX2009009738A (es) 2009-09-24
BRPI0811007A2 (pt) 2015-01-27
EP2139471A2 (en) 2010-01-06
RU2009144142A (ru) 2011-06-10
CL2008001259A1 (es) 2009-01-02
CA2680833A1 (en) 2008-11-13
KR20100014486A (ko) 2010-02-10
AR066292A1 (es) 2009-08-12
WO2008137236A3 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
UY31061A1 (es) Tratamiento de la degeneracion macular relacionada con la edad mediante el uso de inhibidores del factor d del complemento
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
EA201101037A1 (ru) Лечение диабета у пациентов с неадекватным гликемическим контролем, несмотря на лечение метформином
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
UY31497A1 (es) Nuevos compuestos para el tratamiento de trastornos del snc
ECSP11010971A (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un fármaco oral o no oral antidiabético
MX2016016800A (es) Metodos para el tratamiento del sobrepeso o la obesidad.
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
EA201300583A1 (ru) Вазопротективное и кардиопротективное противодиабетическое лечение
CL2015002641A1 (es) Método para el tratamiento de la enfermedad de parkinson.
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
PA8841701A1 (es) Derivados heterocíclicos, procesos para su preparación, medicamentos que comprenden compuestos y su uso
EA200901211A1 (ru) Антигены белка с5 и их применение
MX2012008730A (es) Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares.
ES2689971T3 (es) Uso de inhibidores de PDE7 para el tratamiento de los trastornos del movimiento
NI200800261A (es) Tratamientos de alergia ocular
CY1112414T1 (el) Υλικα οφθαλμικων και ωτορινολαρυγγολογικων συσκευων
UY30901A (es) Nuevos metodos
CY1119867T1 (el) Αναστολεις vap-1 για χρηση στη θεραπεια ινωτικων καταστασεων
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
AR086395A1 (es) Envase para el tratamiento de patologias

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20190902